Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
Date:9/2/2008

Conference Call Scheduled for Today - Tuesday, September 2, 2008 at 5:00

p.m. Eastern Time

MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced positive results from its first Phase 3 clinical trial of AZ-004 (Staccato(R) loxapine) in schizophrenic patients with acute agitation. Both the 5 mg and 10 mg doses of AZ-004 met the primary endpoint of the trial, which was a statistically significant reduction in agitation from baseline to the 2-hour post-dose time point, compared to placebo. AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC.

"Alexza initiated the first Phase 3 clinical trial of our lead program in late February and completed enrollment in less than four months, and today we are reporting positive top-line results for the primary and secondary endpoints," said James V. Cassella, PhD, Alexza Senior Vice President, Research and Development. "We believe that the ability to provide loxapine via our Staccato technology, thus combining a drug with a well-established mechanism of action with rapid absorption and patient self-administration, makes AZ-004 a potentially important new drug candidate for treating acute agitation."

"The clinical data we have seen to date, in terms of both efficacy and side-effect profiles, are compelling," said Michael H. Allen, MD, Director of Research, University of Colorado Depression Center. "There is a significant unmet medical need to treat acute agitation with ne
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
2. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... VEGAS , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... NexGen ® Complete Knee System. ... is the 20 th year since Zimmer first introduced the ... the market. To date, more than five million implantations of the ... year history of the NexGen knee demonstrates the importance of ...
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
... and EVANSTON, Ill., Oct. 20, The American College ... Simulation Research (CESR) of Western Michigan University,announced the ... in,situ simulation to improve the time from hospital ... angioplasty (D2B). Mentice Inc.,was selected as the exclusive ...
... Results Disclosed, SAN DIEGO, Oct. 20 ... "Best-in-Class" drugs for the,treatment of serious bacterial ... studies on its lead program, TR-701, and ... eighteen presentations at the upcoming joint,Interscience Conference ...
Cached Medicine Technology:American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time 2American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time 3American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time 4Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 3
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 DrugDev ... Melissa (Liss) Easy was named to the 2015 Philadelphia ... Under 40 list spotlights 40 dynamic, up-and-coming leaders less ... and community involvement. Winners are honored at an awards ... of the Philadelphia Business Journal. , Lyn Kremer, Publisher ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The report ... an essential source of information on and analysis of ... The population of the US in 2013 amounted to ... Rate (CAGR) of 0.8% from 2008. The country’s increasingly ... chronic diseases will help to boost the growth of ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global ... the SM1120 MEMS based ultra-miniature pressure sensor designed especially ... at only 220um x 75um provides ample space for ... With industry leading in vivo drift performance of ... broad operating pressure range from 0 to 1,100 mmHg ...
(Date:3/27/2015)... When struck with the aftermath of a trucking ... begin. The latest eBook released by Dax Jones ... victims a clear and concise process for obtaining the ... injury claim is seen through to successful completion. , ... should be taken immediately following the trucking incident. From ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... new study shows that monitoring levels of exhaled nitric oxide ... improve the course of their disease. , The study ... is funded by the National Institute of Allergy and Infectious ... The Sept. 20 issue of The Lancet reports ...
... GetResearchSmart LLC serves as Guest Editor for a special issue of ... entitled Measuring Trust in Clinical Research. , ... St. ... of The Monitor, journal of the Association of Clinical Research Professionals ...
... ,do not board, list comes as a surprise to ... -- Thirty-three would-be air travelers with suspected or confirmed ... health "Do Not Board" list in the first year ... , Authorized under the Aviation and Transportation Security Act ...
... National Poll Shows Large Majority Supports Funding ... of the nation,s,largest veterans service organizations, representing ... Veterans, Affairs Committee Chairman Daniel,Akaka (D-Hawaii), House ... a group of bipartisan cosponsors for introducing,legislation ...
... a top concern for businesses of all sizes. Just when,employers ... these that complicate the enrollment:, -- Employees don,t ... of what their employer provides. -- Health ... -- A handful of employees who are located in remote ...
... WHITE PLAINS, N.Y., Sept. 18 Dee Snider,best known as ... Sister,is taking on a new lead role this year as ... is personal: two of his children were,born prematurely, and he,s ... Despite the wild-man image from his heavy metal days, Snider ...
Cached Medicine News:Health News:Monitoring exhaled nitric oxide does not help manage asthma 2Health News:Monitoring exhaled nitric oxide does not help manage asthma 3Health News:GetResearchSmart LLC Website Founder Honored as Guest Editor 2Health News:U.S. Barred 33 TB-Infected People From Flying Over Past Year 2Health News:U.S. Barred 33 TB-Infected People From Flying Over Past Year 3Health News:Historic Legislation to End Delays in Veterans Health Care Funding 2Health News:Historic Legislation to End Delays in Veterans Health Care Funding 3Health News:New Web-Based Enrollment System Gives Employers Flexibility and Control in Managing Benefits Enrollments 2Health News:New Web-Based Enrollment System Gives Employers Flexibility and Control in Managing Benefits Enrollments 3Health News:Dee Snider Joins March of Dimes Bikers for Babies(R) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: